Onesource Specialty Pharma · NSE: ONESOURCE · BSE: 544292
Q4 FY25 results · Jan–Mar 2025
Onesource Specialty Pharma reported revenue from operations of ₹425.95 crore and net profit of ₹98.20 crore for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 425.95 | — | — | 392.56 | +8.5% |
| Other income | 2.89 | — | — | 5.39 | −46.4% |
| Total income | 428.84 | — | — | 397.96 | +7.8% |
| Profit before tax | 83.50 | — | — | (66.50) | Turned profit |
| Net profit for the period | 98.20 | — | — | (68.85) | Turned profit |
| EPS, basic (₹) | 8.61 | — | — | (6.31) | Turned profit |
| Net margin (%) | 23.1 | — | -17.5 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 477.41 | — | — | 336.75 | +41.8% |
| Other income | 3.91 | — | — | 5.01 | −22.1% |
| Total income | 481.32 | — | — | 341.76 | +40.8% |
| Profit before tax | 174.88 | — | — | (73.02) | Turned profit |
| Net profit for the period | 174.19 | — | — | (73.02) | Turned profit |
| EPS, basic (₹) | 15.28 | — | — | (6.69) | Turned profit |
| Net margin (%) | 36.5 | — | -21.7 |
Consolidated
- Filed with BSE
- 05 May 2025, 20:24 IST
- Board meeting
- 05 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 May 2025, 20:24 IST
- Board meeting
- 05 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE